4 ms·

Paper: http://dx.doi.org/10.1038/nature18300 http://dx.doi.org/10.1038/nature18300 Company release: http://biontech.de/2016/06/01/nature-publication-describes-

Paper: http://dx.doi.org/10.1038/nature18300 http://dx.doi.org/10.1038/nature18300 Company release: http://biontech.de/2016/06/01/nature-publication-describes-first-example-of-a-clinically-applicable-and-systemic-mrna-cancer-immunotherapy-vaccine/ http://biontech.de/2016/06/01/nature-publication-describes-f... Really it is pretty random as to what cancer research and development gets more or less attention from the media and public. Merit has little to do with it. You should assume that any given article like this is representative of many similar ones that passed by without comment. The most important thing for any approach aspiring to be widespread in the next generation of cancer research is how costly it is to adapt the platform to any specific cancer. The only way to make real inroads in control of cancer is to crush down the cost of addressing different cancers, making it a small project rather than a whole new research initiative each time around.

hanklazard 10y ago
>The only way to make real inroads in control of cancer is to crush down the cost of addressing different cancers, making it a small project rather than a whole new research initiative each time around. Agreed. And while this study's methods wouldn't be cheap per se, RNA-based methods combined with whole genome sequencing of tumors are much more cost (and time) efficient methods than approaches that require antibodies or chimeric proteins. I believe that these methods, in combination with immunotherapy, are the best candidates for future cancer therapy.
iskander 10y ago
>Merit has little to do with it. Not sure if that's intentional, but the BioNTech series of trials for melanoma been called MERIT (this particular incarnation is Lipo-MERIT).
iskander 10y ago
>Merit has little to do with it. Not sure if that's intentional, but the BioNTech series of trials for melanoma been called MERIT (this particular incarnation is Lipo-MERIT).

hanklazard 10y ago

>The only way to make real inroads in control of cancer is to crush down the cost of addressing different cancers, making it a small project rather than a whole new research initiative each time around. Agreed. And while this study's methods wouldn't be cheap per se, RNA-based methods combined with whole genome sequencing of tumors are much more cost (and time) efficient methods than approaches that require antibodies or chimeric proteins. I believe that these methods, in combination with immunotherapy, are the best candidates for future cancer therapy.

iskander 10y ago

>Merit has little to do with it. Not sure if that's intentional, but the BioNTech series of trials for melanoma been called MERIT (this particular incarnation is Lipo-MERIT).

iskander 10y ago

>Merit has little to do with it. Not sure if that's intentional, but the BioNTech series of trials for melanoma been called MERIT (this particular incarnation is Lipo-MERIT).